Chlamydophila pneumonia vaccine - Antex Biologics
Alternative Names: TWARVAXLatest Information Update: 25 Nov 2004
At a glance
- Originator Antex Biologics
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Chlamydial infections
Most Recent Events
- 25 Nov 2004 Discontinued - Preclinical for Chlamydial infections in USA (unspecified route)
- 25 Aug 2000 Antex has licensed the use of BioSante Pharmaceuticals' calcium phosphate nanoparticle technology as an adjuvant in its Chlamydophila pneumonia vaccine
- 14 May 1999 Preclinical development for Chlamydial infections in USA (Unknown route)